产品说明书
ISA-2011B
 |
同义名 : | - |
| CAS号 : | 1395347-24-6 | |
| 货号 : | A899194 | |
| 分子式 : | C22H18ClN3O4 | |
| 纯度 : | 98+% | |
| 分子量 : | 423.849 | |
| MDL号 : | MFCD30533398 | |
| 存储条件： |
粉末 Sealed in dry,Store in freezer, under -20°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(247.73 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Phosphatidylinositol 4,5-biphosphate kinases (PIP5Ks) are a family of lipid kinases that phosphorylate phosphatidylinositol 4-phosphate on the D5 position of the inositol ring, thus inducing the production of phosphatidylinositol 4,5-biphosphate (PIP2). PIP5K1α is a lipid kinase that acts on PI3K/AKT/PTEN pathways, and thereby regulates cell survival and migration. ISA-2011B is a PIP5Kα inhibitor with promising anticancer effects. Tumor xenografts established with human prostatic carcinoma cell line 22Rv1 were treated with ISA-2011B(40 mg/kg, 2 weeks) and showed a 3.5-fold smaller tumor volumes compared with those treated with vehicle control (mean volume of tumors were 844.12 mm3 and 243.77 mm3 for vehicle-treated and ISA-2011B-treated groups, respectively)[3]. ISA-2011B treatment at 20 mM or 50 mM diminished AR-V7, CDK1 and PSA expression in PIP5K1α-overexpressing and control 22Rv1 cells, and inhibited AR-V7 and pAKT expression in PC3 cells, respectively[3]. ISA-2011B treatment at 10 µM for 6h or 24h significantly impaired the increases in mRNA levels of IL-6, IL-8, and IL-17A in T lymphocytes from healthy donors which were induced by CD38 stimulation[4]. ISA-2011B at 20 μM dramatically inhibited pSer-473 AKT by 75.55% compared with control in LNCaP cells[5]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.36mL 0.47mL 0.24mL |
11.80mL 2.36mL 1.18mL |
23.59mL 4.72mL 2.36mL |
| 参考文献 |
|---|